Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience joins Eli Lilly's TuneLab platform, supplying high-throughput antibody data to train advanced AI drug prediction models.
Stocks · News reference
Twist Bioscience shares are trading higher after the company announced an agreement with Lilly TuneLab to advance antibody drug discovery.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
Twist Bioscience Announces Agreement With Lilly TuneLab To Advance Antibody Drug Discovery